BD HealthSight™ Clinical Advisor and BD HealthSight™ Infection Advisor with MedMined™ Insights (formerly MedMined™ Surveillance Advisor) has earned Meaningful Use Stage 3 (MU3) certification validating its ability to collect and properly report data around antimicrobial use and resistance data by facilities enrolled in the National Healthcare Safety Network (NHSN) that requires reporting for Antimicrobial Use and Resistance (AUR) data in 2022.
Public Health Registry Reporting is a new option for MU3, requiring AUR data to help the Centers for Disease Control and Prevention (CDC) to gain a better understanding of how antibiotic usage impacts resistance in hospitals and healthcare facilities. The objective calls for reporting a full calendar year's data on R1 Normative Antimicrobial Use Summary, Antimicrobial Resistance Event, and Antimicrobial Resistance summary data to be reported using clinical documentation architecture (CDA) formatting.
By submitting AUR data into the NHSN platform, clinicians can benchmark their antibiotic usage and organism resistance data nationally to target areas for improvement.
By leveraging data from a hospital's electronic medical record, physician order entry, laboratory and pathology systems to monitor patients for adverse drug events and interactions, BD HealthSight™ Clinical Advisor and BD HealthSight™ Infection Advisor with MedMined™ Insights can alert clinicians and pharmacists and identify opportunities for antimicrobial stewardship across the continuum of care.
